MY165614A - Formulations of antibody - Google Patents
Formulations of antibodyInfo
- Publication number
- MY165614A MY165614A MYPI2012002248A MYPI2012002248A MY165614A MY 165614 A MY165614 A MY 165614A MY PI2012002248 A MYPI2012002248 A MY PI2012002248A MY PI2012002248 A MYPI2012002248 A MY PI2012002248A MY 165614 A MY165614 A MY 165614A
- Authority
- MY
- Malaysia
- Prior art keywords
- formulations
- antibody
- lyoprotectants
- cryoprotectants
- buffer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000002577 cryoprotective agent Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2859CH2009 | 2009-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY165614A true MY165614A (en) | 2018-04-18 |
Family
ID=44059267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2012002248A MY165614A (en) | 2009-11-20 | 2010-11-19 | Formulations of antibody |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US20120231009A1 (en, 2012) |
| EP (2) | EP3721904B1 (en, 2012) |
| JP (2) | JP5896471B2 (en, 2012) |
| KR (1) | KR101333276B1 (en, 2012) |
| CN (1) | CN102770157B (en, 2012) |
| AU (1) | AU2010320515B2 (en, 2012) |
| BR (1) | BR112012012080B1 (en, 2012) |
| CA (1) | CA2781467C (en, 2012) |
| CU (1) | CU20120080A7 (en, 2012) |
| DK (1) | DK3721904T3 (en, 2012) |
| ES (1) | ES2897500T3 (en, 2012) |
| IL (1) | IL219884A (en, 2012) |
| MX (1) | MX2012005863A (en, 2012) |
| MY (1) | MY165614A (en, 2012) |
| NZ (1) | NZ600096A (en, 2012) |
| PL (1) | PL3721904T3 (en, 2012) |
| PT (1) | PT3721904T (en, 2012) |
| RU (1) | RU2548772C2 (en, 2012) |
| WO (1) | WO2011061712A1 (en, 2012) |
| ZA (1) | ZA201204459B (en, 2012) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| MX2010010085A (es) | 2008-03-14 | 2011-03-29 | Biocon Ltd | Un anticuerpo monoclonal y el metodo para su uso. |
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| EP3326648B1 (en) | 2011-01-28 | 2021-03-10 | Sanofi Biotechnology | Pharmaceutical compositions comprising human antibodies to pcsk9 |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| AU2012308797B2 (en) | 2011-09-16 | 2017-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9) |
| MX357393B (es) | 2012-01-23 | 2018-07-06 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti - ang2. |
| AR092325A1 (es) | 2012-05-31 | 2015-04-15 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit |
| SG10201705668XA (en) | 2012-09-07 | 2017-08-30 | Coherus Biosciences Inc | Stable aqueous formulations of adalimumab |
| CN102961745B (zh) * | 2012-09-27 | 2015-02-18 | 苏州康聚生物科技有限公司 | 抗体组合物制剂及其应用 |
| TR201809507T4 (tr) | 2012-11-06 | 2018-07-23 | Bayer Pharma AG | Bispesifik T-hücresi bağlayıcıları (BİTE'ler) için formülasyon. |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| US10189899B2 (en) | 2013-07-23 | 2019-01-29 | Biocon Limited | Use of a CD6 binding partner and method based thereon |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| TWI670077B (zh) | 2013-11-12 | 2019-09-01 | 賽諾菲生物技術公司 | 使用ｐｃｓｋ９抑制劑之給藥療程 |
| JP6707469B2 (ja) * | 2014-05-28 | 2020-06-10 | ノノ インコーポレイテッド | アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤 |
| CA2955294A1 (en) | 2014-07-16 | 2016-01-21 | Sanofi Biotechnology | Methods for treating patients with heterozygous familial hypercholesterolemia (hefh) |
| AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| CN104922668B (zh) * | 2014-12-10 | 2019-08-23 | 信达生物制药(苏州)有限公司 | 一种稳定的抗vegf抗体制剂及其用途 |
| KR101776879B1 (ko) * | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| EP3337828B1 (en) | 2015-08-18 | 2025-08-27 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| KR102546471B1 (ko) * | 2016-09-27 | 2023-06-21 | 프레제니우스 카비 도이치란트 게엠베하 | 액상의 약학 조성물 |
| PL3529274T3 (pl) | 2016-10-21 | 2024-09-09 | Biocon Limited | Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia |
| CN106800598B (zh) * | 2017-02-09 | 2020-08-07 | 广州桂雨生物科技有限公司 | 一种抗体保存液及其制备方法 |
| EP3768706A1 (en) * | 2018-03-23 | 2021-01-27 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
| CN111110841A (zh) * | 2018-10-31 | 2020-05-08 | 上海君实生物医药科技股份有限公司 | 含有抗pcsk9抗体的稳定制剂 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| WO2021136274A1 (zh) * | 2019-12-30 | 2021-07-08 | 百奥泰生物制药股份有限公司 | 含抗Trop2抗体-药物偶联物的制剂及其制备方法和应用 |
| US11498626B2 (en) * | 2020-11-11 | 2022-11-15 | Rivian Ip Holdings, Llc | Vehicle tailgate assembly |
| CN113289027B (zh) * | 2021-05-18 | 2022-07-01 | 中国兽医药品监察所 | 一种通用型单克隆抗体耐热保护剂 |
| TW202417512A (zh) * | 2022-10-17 | 2024-05-01 | 英屬開曼群島商百濟神州有限公司 | 含有抗tigit抗體的配製物及其使用方法 |
| CN117214426A (zh) * | 2023-09-20 | 2023-12-12 | 暨南大学 | 一种用于免疫组织化学检测的抗体稀释液及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1151842C (zh) * | 1995-07-27 | 2004-06-02 | 基因技术股份有限公司 | 稳定等渗的冻干蛋白制剂 |
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5810597A (en) * | 1996-06-21 | 1998-09-22 | Robert H. Allen, Jr. | Touch activated audio sign |
| EP2311492B1 (en) | 2000-08-11 | 2017-10-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing stabilized preparations |
| DE60235013D1 (de) * | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| MXPA05010555A (es) * | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| EP1933873A4 (en) * | 2005-10-13 | 2009-12-02 | Human Genome Sciences Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PATIENTS WITH POSITIVE DISEASES FOR SELF-ANTIBODIES |
| WO2007147001A2 (en) * | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
| CA2671968A1 (en) * | 2006-12-11 | 2008-06-19 | F. Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
| CN101199483B (zh) * | 2006-12-14 | 2011-01-26 | 上海中信国健药业股份有限公司 | 一种稳定的抗her2人源化抗体制剂 |
| PT2119453E (pt) * | 2006-12-26 | 2015-09-01 | Ct De Inmunolgã A Molecular | Composições farmacêuticas capazes de induzir apoptose em células tumorais, úteis para o diagnóstico e o tratamento da leucemia linfocítica crónica de células |
| WO2008086395A2 (en) * | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| AU2008269086B2 (en) * | 2007-06-25 | 2014-06-12 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| WO2009037190A2 (en) * | 2007-09-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for il-ir antibody |
-
2010
- 2010-11-19 WO PCT/IB2010/055296 patent/WO2011061712A1/en active Application Filing
- 2010-11-19 ES ES20174783T patent/ES2897500T3/es active Active
- 2010-11-19 BR BR112012012080-8A patent/BR112012012080B1/pt active IP Right Grant
- 2010-11-19 NZ NZ600096A patent/NZ600096A/xx unknown
- 2010-11-19 US US13/510,929 patent/US20120231009A1/en not_active Abandoned
- 2010-11-19 KR KR1020127015910A patent/KR101333276B1/ko active Active
- 2010-11-19 RU RU2012125254/15A patent/RU2548772C2/ru active
- 2010-11-19 EP EP20174783.9A patent/EP3721904B1/en active Active
- 2010-11-19 JP JP2012539465A patent/JP5896471B2/ja active Active
- 2010-11-19 AU AU2010320515A patent/AU2010320515B2/en active Active
- 2010-11-19 MY MYPI2012002248A patent/MY165614A/en unknown
- 2010-11-19 DK DK20174783.9T patent/DK3721904T3/da active
- 2010-11-19 EP EP10831248.9A patent/EP2501408B1/en active Active
- 2010-11-19 CN CN201080060508.0A patent/CN102770157B/zh active Active
- 2010-11-19 PL PL20174783T patent/PL3721904T3/pl unknown
- 2010-11-19 CA CA2781467A patent/CA2781467C/en active Active
- 2010-11-19 PT PT201747839T patent/PT3721904T/pt unknown
- 2010-11-19 MX MX2012005863A patent/MX2012005863A/es active IP Right Grant
-
2012
- 2012-05-20 IL IL219884A patent/IL219884A/en active IP Right Grant
- 2012-05-21 CU CU2012000080A patent/CU20120080A7/es unknown
- 2012-06-18 ZA ZA2012/04459A patent/ZA201204459B/en unknown
-
2015
- 2015-12-28 JP JP2015256586A patent/JP2016104780A/ja active Pending
-
2018
- 2018-11-20 US US16/197,228 patent/US20190321285A1/en not_active Abandoned
-
2020
- 2020-10-30 US US17/085,316 patent/US20210290525A1/en not_active Abandoned
-
2023
- 2023-05-19 US US18/199,675 patent/US20240058263A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY165614A (en) | Formulations of antibody | |
| PH12013500225A1 (en) | Stabilized formulations containing anti-ngf antibodies | |
| CY1121233T1 (el) | Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r) | |
| PH12014502778A1 (en) | Antibody formulation | |
| PH12014502460A1 (en) | Lyophilised and aqueos anti-cd40 antibody formulations | |
| PH12012501370B1 (en) | Stabilized formulations containing anti-interleukin -6- receptor (il-6r) antibodies | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| AU2009215514A9 (en) | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same | |
| TN2009000382A1 (en) | Stable antibody formulations | |
| MX2013002048A (es) | Conjugados, particulas, composiciones y metodos relacionados. | |
| MY197851A (en) | Antibody formulations | |
| CL2012003654A1 (es) | Formulación farmaceutica estable para administracion intratecal que comprende una proteina arilsulfatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que ademas puede contener un agente estabilizante; contenedor que comprende dicha formulacion; uso para tratar la enfermedad leucodistrofia metacromática (mld). | |
| MY172245A (en) | Subcutaneous anti-her2 antibody formulation | |
| MX344795B (es) | Composiciones y metodos para suministro al sistema nervioso central de arilsulfatasa a. | |
| WO2010021607A3 (en) | Pharmaceutical formulation | |
| UA103025C2 (ru) | Твердая композиция лекарственного средства замедленного высвобождения | |
| WO2010053610A3 (en) | Stable anthrax vaccine formulations | |
| WO2011002422A3 (en) | Solubility enhancing pharmaceutical formulation | |
| WO2011093831A3 (en) | Effervescent formulations comprising cefprozil as active agent | |
| MX366768B (es) | Tableta orodispersable de sildenafil y metodo para preparar la misma. | |
| PH12014500432A1 (en) | Stable compositions and methods for preparing the same | |
| 高蕾 et al. | Human umbilical cord blood-derived stromal cells: multifaceted regulators of megakaryocytopoiesis | |
| TH125691A (th) | สูตรของแอนตี้บอดี้ | |
| HK1169945A (en) | Methods and compositions for stable liquid drug formulations | |
| HK1195489A (en) | Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same |